# CONDENSED INTERIM FINANCIAL STATEMENTS

For the three and nine months ended July 31, 2024, and 2023

(Expressed in Canadian dollars)

(Unaudited)

Condensed Interim Statements of Financial Position As at July 31, 2024 and October 31, 2023 (Unaudited - Expressed in Canadian dollars)

	Nata		July 31,		October 31,
	Notes		2024		2023
ASSETS					
Current assets					
Cash		\$	10,187	\$	51,644
Accounts receivable and other receivables	4		39,204		48,473
Prepaid expenses			5,621		16,555
Inventory	5,11		-		59,772
			55,012		176,444
Equipment and right-of-use asset	6,11		12,976		15,275
Total assets		\$	67,988	\$	191,719
LIABILITIES Current liabilities		•		•	
Bank indebtedness		\$	-	\$	-
Accounts payable and accrued liabilities	8,11		434,602		329,998
			434,602		329,998
SHAREHOLDERS' (DEFICIENCY) EQUITY					
Share capital	9		2,185,912		1,802,680
Share subscriptions	9		3,300		95,500
Share-based payments reserve	9		954,829		924,862
Deficit			(3,510,655)		(2,961,321)
Total shareholders' deficiency			(366,614)		(138,279)
Total liabilities and shareholders' equity		\$	67,988	\$	191,719

Nature of operations and going concern (Note 1) Subsequent Events (Note 16, 17)

Approved and authorized for	issue by the Board of I	Directors on October 1, 2024:	
"Pratapvir Sandhu"	Director	"Ajit Bhatti"	Director

Condensed Interim Statements of Loss and Comprehensive Loss For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

	Notes		Three months ended July 31, 2024		Three months ended July 31, 2023		Nine months ended July 31, 2024		Nine months ended July 31, 2023
Revenue	10,11	\$		\$	18,303	\$	11,122	\$	282,984
Cost of sales	5	·	-	·	(16,966)	,	(7,692)	·	(273,826)
Gross profit	-		-		1,337		3,430		9,158
Expenses			5.000		22.204		40.220		224.250
Advertising and promotion	•		5,000		33,264		48,336		321,250
Depreciation	6		349		207		763		3,950
Office and administrative	11		6,647		9,219		29,327		45,882
Professional fees	11		12,040		98,670		153,234		424,440
Rent	44		10,500		10,500		31,500		30,625
Salaries and wages	11		- 25 467		39,853		117,338		105,694
Share-based payments	9		35,467		54,851		110,949		279,412
Total operating expenses			70,003		246,564		491,447		1,211,253
Loss before other items			(70,003)		(245,227)		(488,017)		(1,202,095)
Other items Foreign exchange gain (loss) Impairment of inventory	5		-		(551) -		55 (61,372)		(4,430)
Net loss and comprehensive loss for the period		\$	(70,003)	\$	(245,778)	\$	(549,334)	\$	(1,206,525)
					<u> </u>		<u> </u>		
Weighted average number of shares – Basic and diluted			38,985,332		36,504,131		37,533,355		32,202,400
Loss per share – Basic and diluted		\$	(0.00)	\$	(0.01)	\$	(0.01)	\$	(0.04)

Condensed Interim Statements of Changes in Shareholders' Deficiency For the nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

	Share ca	pital				
	Number					
	of		Share-based	Obligation		Total
	common	Share	payments	to issue		shareholders'
	shares	capital	reserve	shares	Deficit	deficiency
Balance, October 31, 2022	27,635,001	801,197	718,571	-	(1,308,003)	211,765
Units issued from private placement	7,650,000	765,000	-	-	-	765,000
Share issuance cost	-	(40,013)	12,391	-	-	(27,622)
Share-based payments	-	-	279,412	-	-	279,412
Shares issued for exercised warrants	1,230,000	201,000	(75,000)	-	-	126,000
Net loss and comprehensive loss for the period	-	-	-	-	(1,206,525)	(1,206,525)
Balance, July 31, 2023	36,515,001 \$	1,727,184 \$	935,374	\$ -	(2,514,528)	\$ 148,030
Balance, October 31, 2023	36,948,334	1,802,680	924,862	95,500	(2,961,321)	(138,279)
Units issued from private placement	2,036,998	236,440	69,110	(95,500)	-	210,050
Obligation to issue shares	-	_	(3,300)	3,300	-	-
Shares issued for RSU exercise	813,334	146,792	(146,792)	-	-	-
Share-based payments – RSU	-	-	110,949	-	-	110,949
Net loss and comprehensive loss for the period	-	-	-	-	(549,334)	(549,334)
Balance, July 31, 2024	39,798,666 \$	2,185,912 \$	954,829	\$ 3,300	(3,510,655)	\$ (366,614)

Pangea Natural Foods Inc.
Condensed Interim Statements of Cash Flows For the nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

	Notes	Nine months ended July 31, 2024		Nine months ended July 31, 2023
Operating activities		(= 10 00 1)	•	(4.000.505)
Net loss for the period		\$ (549,334)	\$	(1,206,525)
Items not affecting cash:				
Depreciation	6	700		6,254
Impairment of inventory	5	61,372		5,769
Share-based payments	9	110,949		279,412
Non-cash working capital items:				
Accounts receivable and other receivables		9,268		7,494
Prepaid expenses		10,934		155,179
Inventory		-		(17,105)
Accounts payable and accrued liabilities		104,604		13,701
Net cash used in operating activities		(251,507)		(755,821)
Financing activities				
Proceeds from issuance of units	9	210,050		765,000
Proceeds from exercised warrants				126,000
Share issuance costs		-		(27,622)
Net cash provided by financing activities		210,050		863,378
Change in cash		(41,457)		107,557
Cash, beginning of period		51,644		75,951
Cash (Cash Deficit), end of period		\$ 10,187	\$	183,508
Supplemental cash flow information: Finder's warrants issued		\$ _	\$	12,391

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

#### 1. NATURE OF OPERATIONS AND GOING CONCERN

Pangea Natural Foods Inc. ("Pangea" or the "Company") was incorporated on April 10, 2021 under the laws of the British Columbia Business Corporations Act. The registered records office of Pangea is located at 10<sup>th</sup> Floor, 595 Howe Street, Vancouver B.C. V6C 2T5. On July 4, 2022, the Company listed its common shares on the Canadian Securities Exchange under the trading symbol "PNGA".

The Company manufactures and distributes high quality food products that are nutritious and free of GMO ingredients, fillers, antibiotics, hormones, and bioengineered ingredients.

The financial statements have been prepared on the basis on accounting principles applicable to a going concern which assumes the Company will be able to continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The Company's ability to continue as a going concern and to realize assets at their carrying values is dependent upon its ability to obtain financing and generate profits and positive cash flows from operations in order to cover its operating costs.

The Company incurred a loss of \$549,334for the nine months ended July 31, 2024 (July 31, 2023 – (\$1,206,525)), and as of that date the Company's accumulated deficit was \$3,510,655 (October 31, 2023 – \$2,961,321). The Company will periodically need to raise funds to continue its operations and although it has been successful in doing so in the past, there is no assurance that it will be able to continue to do so in the future. These events and conditions indicate a material uncertainty which may cast significant doubt about the Company's ability to continue as a going concern. These financial statements do not give effect to any adjustments required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying financial statements. These adjustments could be material.

## 2. BASIS OF PRESENTATION

#### a) Statement of compliance

These condensed interim financial statements have been prepared in accordance with International Accounting Standards ("IAS") 34 - Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB").

They have been prepared in accordance with the same accounting policies and methods of application as the audited financial statements for the year ended October 31, 2023, except that they do not include all the disclosures required for the annual audited financial statements. These condensed interim financial statements should be read in conjunction with the audited financial statements for the Company for the year ended October 31, 2023.

#### b) Basis of measurement

These condensed interim financial statements have been prepared on a historical cost basis, except for any financial assets and liabilities measured at fair value. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting except for cash flow information. The condensed interim financial statements are presented in Canadian dollars, unless otherwise noted.

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

# 2. BASIS OF PRESENTATION (continued)

# c) Significant accounting policies

These condensed interim financial statements should be read in conjunction with the Company's audited financial statements for the year ended October 31, 2023. The significant accounting policies applied in the preparation of these condensed interim financial statements are consistent with the accounting policies disclosed in Note 3 of the audited financial statements for the year ended October 31, 2023.

### 3. MANAGEMENT'S USE OF JUDGEMENTS AND ESTIMATES

The preparation of these condensed interim financial statements in accordance with IFRS requires management to make estimates, judgements and assumptions that affect the reported amount of assets and liabilities and the disclosure of contingent liabilities at the date of the condensed interim financial statements and the reported amount of income and expenses during the period. Actual results could differ from these estimates.

In preparing these condensed interim financial statements, the significant estimates and critical judgements were the same as those applied to the audited financial statements as at and for the year ended October 31, 2023.

#### 4. ACCOUNTS RECEIVABLE AND OTHER RECEIVABLES

	July 31, 2024	October 31, 2023
Accounts receivable (Note 11)	\$ 66,952	\$ 71,864
Expected credit loss (Note 13)	(31,695)	(31,694)
Sales tax recoverable	3,947	8,303
	\$ 39,204	\$ 48,473

#### 5. INVENTORY

	Ju	ıly 31, 2024	October 31, 2023
Finished goods	\$	- \$	2,638
Packaging materials		-	57,134
	\$	- \$	59,772

During the nine months ended July 31, 2024, the Company impaired 100% of its remaining inventory on hand, and recorded an impairment loss in profit and loss of \$61,372 (July 31, 2023 - \$Nil).

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

# 6. EQUIPMENT AND RIGHT-OF-USE ASSET

		mputer iipment		luction pment	•	t-of-use sset	1	otal
Cost	-		-	•				
Balance, October 31, 2022								
and 2023	\$	2,481	\$	21,500	\$	43,392	\$	67,373
Additions		-		-		-		-
Balance, July 31, 2024	\$	2,481	\$	21,500	\$	43,392	\$	67,373
Accumulated depreciation								
Balance, October 31, 2022	\$	1,223	\$	3,585	\$	40,063	\$	44,871
Depreciation		827		3,071		3,329		7,227
Balance, October 31, 2023		2,050		6,656		43,392		52,098
Depreciation		431		1,868		_		2,299
Balance, July 31, 2024	\$	2,481	\$	8,524	\$	43,392	\$	54,397
Carrying amounts								
At October 31, 2023	\$	431	\$	14,844	\$	_	\$	15,275
At July 31, 2024	\$	-	\$	12,976	\$	-	\$	12,976

### 7. INTANGIBLE ASSETS

During the year ended October 31, 2022, the Company acquired the formula which forms the basis for their plant-based nuggets.

During the year ended October 31, 2023, the Company completed its annual impairment testing of the patty formula and nugget formula. As a result of the impairment tests, the Company determined that the carrying value of the patty formula and nugget formula were higher than its recoverable amount and recognized an impairment loss of \$8,200 during the year ended October 31, 2023.

	Patty	formula	Nugget	formula	Total
Cost					
Balance, October 31, 2022		1,000		7,200	8,200
Impairment		(1,000)		(7,200)	(8,200)
Balance, October 31, 2023, and July 31, 2024	\$	-	\$	-	\$ -
Carrying amounts					
At October 31, 2023, and July 31, 2024	\$	-	\$	-	\$ -

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

#### 8. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	July 31,	October 31,
	2024	2023
Trade payables (Note 11)	\$ 262,121	\$ 235,339
Accrued liabilities (Note 11)	151,266	80,654
Payroll payable	21,215	14,005
	\$ 434,602	\$ 329,998

#### 9. SHARE CAPITAL

# Authorized capital

The Company is authorized to issue an unlimited number of commons shares without par value.

# Issued and outstanding capital

As at July 31, 2024, there were 39,798,666 common shares issued and outstanding.

For the nine months ended July 31, 2024

On November 7, 2023, the Company closed the first tranche of the non-brokered private placement. The Company issued 1,636,998 units at a price of \$0.15 per unit for gross proceeds of \$245,550. Each unit consists of one common share and one half of one share purchase warrant. Each warrant entitles the warrant holder to acquire one additional common share of the Company at an exercise price of \$0.25 for a period of 24 months from the date of closing. The warrants were valued using the residual value method and assigned a value of \$49,110.

On January 26, 2024, the Company closed the second tranche of the non-brokered private placement. The Company issued 400,000 units at a price of \$0.15 per unit for gross proceeds of \$60,000. Each unit consists of one common share and one half of one share purchase warrant. Each warrant entitles the warrant holder to acquire one additional common share of the Company at an exercise price of \$0.25 for a period of 24 months from the date of closing. The warrants were valued using the residual value method and assigned a value of \$20,000.

For the nine months ended July 31, 2023

On November 21, 2022, the Company issued 700,000 common shares pursuant to the exercise of warrants at a price of \$0.10 per common share for gross proceeds of \$70,000. In connection with the issuance, \$42,000 was transferred from share-based payments reserve to share capital.

On February 13, 2023, the Company completed a private placement, issuing 7,650,000 units at a price of \$0.10 per unit for gross proceeds of \$765,000. Each unit consists of one common share and one half of one common share purchase warrant. Each warrant entitles the warrant holder to acquire one additional common share of the Company at an exercise price of \$0.20 for a period of 24 months commencing on the date of issuance. In connection with the private placement, the Company issued 128,000 finder's warrants, paid a cash finder's fee of \$12,800 and legal fees of \$14,822. The finder's warrants have the same terms as those in the private placement unit.

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

# 9. SHARE CAPITAL (continued)

#### Escrowed common shares

On July 4, 2024, 3,540,000 shares were released from escrow. As at July 31, 2024, the Company had 6,780,001 common shares held in escrow (October 31, 2023 – 13,860,001). The common shares are being released from escrow 10% on the listing date of July 4, 2022 and 15% every six months after the listing date. All securities will be release from escrow by thirty-six months after the listing date.

# Warrants

Continuity of the Company's warrants is as follows:

	Numbers of warrants	Weighted average exercise price
Outstanding, October 31, 2022	8,417,500	\$ 0.14
Issued	3,953,000	0.20
Exercised*	(1,230,000)	0.10
Expired	(7,112,500)	0.15
Outstanding, October 31, 2023	4,028,000	0.20
Issued	1,018,500	0.24
Expired	(75,000)	0.20
Outstanding, July 31, 2024	4,971,500	\$ 0.21

<sup>\*</sup>The weighted average market price of the Company's common shares on the date of exercise was \$0.15.

As at July 31, 2024, the following warrants were outstanding:

Grant date	Warrants outstanding	Exercise price	Expiry date	Remaining contractual life (years)
February 13, 2023	3,825,000	\$0.20	February 13, 2025	0.79
February 13, 2023	128,000	\$0.20	February 13, 2025	0.79
November 7, 2023	818,500	\$0.25	November 7, 2025	1.52
January 26, 2024	200,000	\$0.25	January 26, 2026	1.74
	4,971,500	\$0.21		0.95

The Company uses the Black-Scholes option pricing model to estimate the fair value of the finder's warrants granted. The following assumptions were used:

	2023
Stock Price	\$0.18
Exercise price	\$0.20
Dividend yield	Nil
Forfeiture rate	Nil
Annualized volatility	105%
Risk-free interest rate	4.07%
Expected life	2 years

Annualized volatility was derived from a sample of similar publicly traded companies.

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

# 9. SHARE CAPITAL (continued)

### **Options**

On February 13, 2023, the Company's Board of Directors approved the adoption of a new rolling 15% omnibus share incentive plan (the "Plan") to supersede the Company's existing rolling 10% incentive stock option plan. The Plan provides for the award of additional share-based payments in addition to incentive stock options, including restricted share units, performance share units and deferred share units to directors, officers, employees and consultants of the Company.

The aggregate number of shares reserved for issuance pursuant to awards granted under this Plan shall not exceed 15% of the Company's total issued and outstanding common shares. If any outstanding award expires or otherwise terminates for any reason without having been exercised or settled in cash, the number of shares in respect of such expired or terminated award shall again be available for issuance under the Plan.

The grant date and the expiry date of an option shall be the dates fixed by the Board at the time the options are granted, with the expiry date not exceeding ten years from the grant date and shall be set out in the option certificate issued in respect of such option. The exercise price shall also be determined by the Board and set out in the certificate issued in respect of the option and shall not be less than the greater of the closing market price prevailing on the date prior to the date of grant and the date of grant of such option.

Continuity of the Company's options is as follows:

	Number of options	Weighted average exercise price		
Outstanding, October 31, 2022	2,300,000	\$ 0.10		
Granted	1,047,750	0.18		
Forfeited	(850,000)	0.12		
Outstanding, October 31, 2023, and July 31, 2024	2,497,750	\$ 0.13		

As at July 31, 2024, the following options were outstanding:

Options outstanding	Options exercisable	Exercise price	Expiry date	Remaining contractual life (years)
1,650,000	1,650,000	\$0.10	February 14, 2027	2.79
847,750	847,750	\$0.18	February 13, 2026	1.79
2,497,750	2,497,750	\$0.13		2.45

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

# 9. SHARE CAPITAL (continued)

#### **Options**

The Company uses the Black-Scholes option pricing model to estimate the fair value of the options granted. The following assumptions were used:

	2023
Stock Price	\$0.18
Exercise price	\$0.18
Dividend yield	Nil
Forfeiture rate	Nil
Annualized volatility	117%
Risk-free interest rate	3.75%
Expected life	3 years

Annualized volatility was derived from a sample of similar publicly traded companies.

# Restricted Share Units ("RSUs")

On January 16, 2024, 180,000 RSUs were granted to a consultant of the Company. The granted RSUs will vest over 6 months from the grant date, with a sixth vesting every month.

On December 8, 2023, 180,000 RSUs were granted to a consultant of the Company. The granted RSUs will vest over 6 months from the grant date, with a sixth vesting every month.

On September 22, 2023, the Company granted 264,000 RSUs to a consultant of the Company. The granted RSUs will vest over 6 months from the date of grant, with a sixth vesting every month.

On February 13, 2023, pursuant to the Company's Plan, the Company granted 2,050,000 RSUs to consultants of the Company. 1,850,000 of the RSUs will vest over 18 months from the date of grant, with a third vesting every six months. The remaining 200,000 RSUs will vest on April 16, 2024.

The fair value of the RSUs is determined by the quoted market price of the Company's common shares at date of grant. Share-based payment is recognized in profit or loss over the vesting period.

At the discretion of the Board of Directors, RSUs may be settled in equity, cash or a combination of both. The fair value of RSUs, which are settled in equity, is recognized as a share-based payment with a corresponding increase in share-based payments reserve, over the vesting period. The fair value of RSUs, when settled in cash, is recognized as a share-based payment with a corresponding increase in liabilities, over the vesting period.

During the nine months ended July 31, 2024, the Company recognized share-based payments of \$110,949 (July 31, 2023 – \$146,386) relating to the vesting of the RSUs. During the nine months ended July 31, 2024, 264,000 previously granted RSUs were cancelled, and \$35,843 in share-based payments were reversed.

As at July 31, 2024, the Company had 613,333 RSUs outstanding (October 31, 2023 – 1,330,667).

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

# 9. SHARE CAPITAL (continued)

# Restricted Share Units ("RSUs") (continued)

Continuity of the Company's RSUs is as follows:

	Number of Restricted Share Units
Balance, October 31, 2022	-
Granted	2,314,000
Exercised	(433,333)
Forfeited	(550,000)
Balance, October 31, 2023	1,330,667
Granted	360,000
Exercised	(813,334)
Cancelled	(264,000)
Balance, July 31, 2024	613,333

# 10. REVENUE

The Company generates revenue primarily from the sale of its plant-based patties and Old-Fashioned Ghee. The Company also generates revenue from the sale of other food products as well as the sale of raw food products.

Revenue is currently generated in one geographical market, being Canada, and is recognized upon delivery of purchase orders to customers.

#### 11. RELATED PARTY TRANSACTIONS

Related parties consist of the directors, officers and companies owned or controlled in whole or in part by them. Related parties and related party transactions impacting the financial statements not disclosed elsewhere in these financial statements are summarized below.

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. Key management personnel comprise officers and directors of the Company.

Remuneration attributed to key management personnel is summarized as follows:

	Three months ended July 31, 2024	Three months ended July 31, 2023	Nine months ended July 31, 2024	Nine months ended July 31, 2023
Salaries and wages	\$ -	\$ 34,061	\$ 62,400 \$	96,728
Professional fees Advertising and	-	26,696	30,279	110,067
promotion	-	-	-	10,000
Share-based payments	-	-	-	12,411
	\$ -	\$ 60,757	\$ 92,679 \$	168,449

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

# 11. RELATED PARTY TRANSACTIONS (continued)

As at July 31, 2024, included in accounts payable and accrued liabilities was \$33,241 (October 31, 2023 - \$20,464) owed to the CEO of the Company, \$50,049 (October 31, 2023 - \$50,563) owed to a management entity for the provision of CFO services, \$3,311 (October 31, 2023 - \$3,311) owed to a company owned by a director of the Company, and \$72,033 (October 31, 2023 - \$45,866) owed to companies that the CEO of the Company has significant influence over.

#### Other transactions

During the nine months ended July 31, 2024, the Company incurred \$Nil (July 31, 2023 - \$2,748) for purchases of inventory and completed sales of raw materials to a company owned by a director of the Company in the amount of \$Nil (July 31, 2023 – \$127,252).

During the nine months ended July 31, 2024, the Company incurred \$6,027 (July 31, 2023 - \$58,876) for purchases of inventory, \$Nil (July 31, 2023 - \$1,620) for labour included in inventory, and \$Nil (July 31, 2023 - \$31,500) for rent to companies that the CEO of the Company has significant influence over.

#### 12. CAPITAL MANAGEMENT

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern to support its business plan, as well as to ensure that the Company is able to meet its financial obligations as they become due. The Company considers its capital for this purpose to be shareholders' equity.

The basis for the Company's capital structure is dependent on the Company's expected business growth and changes in business environment. To maintain or adjust the capital structure, the Company may seek additional funding.

The Company believes it will be able to raise capital as required but recognizes there will be risks involved that may be beyond its control. There are no external restrictions on the management of capital. There have been no changes in the way in which the Company manages capital in the year. As at July 31, 2024, the Company expects its capital resources and projected future cash flows from operations to support its normal operating requirements on an ongoing basis. As at July 31, 2024, there were no externally imposed restrictions on the capital, or management thereof, of the Company.

### 13. FINANCIAL RISK MANAGEMENT

#### Fair values

The Company's financial instruments consist of cash, accounts receivable, and accounts payable and accrued liabilities. Cash is carried at fair value through profit or loss, while accounts receivable and accounts payable and accrued liabilities are carried at amortized cost. The fair values of accounts receivable, and accounts payable and accrued liabilities approximate their carrying values due to their short terms to maturity.

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

# 13. FINANCIAL RISK MANAGEMENT (continued)

The Company classifies its financial assets at FVTPL according to the fair value hierarchy as follows:

Level 1 - fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 - fair value measurements are those derived from inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3 - fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

As at July 31, 2024 and October 31, 2023, cash was measured at FVTPL in accordance with Level 1 of the fair value hierarchy. The Company had no transfers between levels of the fair value hierarchy during the nine months ended July 31, 2024.

#### Financial risks

The Company is exposed in varying degrees to a variety of financial instrument-related risks. Significant risks that are relevant to the Company, as well as methods to manage the various types of risk to which it is exposed, are discussed below:

#### Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprised three types of risk: foreign currency risk, interest rate risk and other price risk.

## Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate as a result of changes in foreign exchange rates. The Company's functional and presentation currency is the Canadian dollar and financings, and major purchases are transacted in Canadian dollars. As a result, the Company's exposure to the foreign currency risk is not considered to be material. The Company has not had a material change in or management of this risk during the six months ended July 31, 2024.

#### Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Interest earned on cash is insignificant and the Company does not rely on interest income to fund its operations. As a result, the Company's exposure to interest rate risk is not considered to be material. The Company has not had a material change in or management of this risk during the six months ended July 31, 2024.

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

# 13. FINANCIAL RISK MANAGEMENT (continued)

# Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices, whether those changes are caused by factors specific to the individual financial instrument or its issuer or by factors affecting all similar financial instruments traded in the market. The Company does not hold equity investments in other entities and therefore is not exposed other price risk. The Company's exposure to and management of this risk has not changed materially during the nine months ended July 31, 2024.

#### Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company's cash and accounts receivable are exposed to credit risk. The Company reduces its credit risk on cash by placing these instruments with either major financial institutions or reputable institutions with a sufficiently long operating history to be considered reliable for credit worthiness purposes. The Company mitigates credit risk by monitoring its exposure for credit losses with customers. 50% of the accounts receivable balance at July 31, 2024 relates to two customers (October 31, 2023 – 87%). The Company has determined that a provision of \$31,695 (October 31, 2023 - \$31,695) for expected credit losses is required as the amount is considered not collectible.

# Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Company manages liquidity risk through the management of its capital structure. The Company addresses its liquidity by raising capital through the issuance of equity to supplement revenues from operations. While the Company has been successful in securing financings in the past, there is no assurance that it will be able to do so in the future.

The tables below summarize the maturity profile of the Company's financial liabilities based on the remaining period to the contractual maturity date as at July 31, 2024 and October 31, 2023.

		Less	than 1			
July 31, 2024	On-demand		year	1-3 y	ears	Total
Accounts payable and accrued liabilities	\$434,602	\$	-	\$	-	\$434,602
		Less	than 1			
October 31, 2023	On-demand		year	1-3 y	ears	Total
Accounts payable and accrued liabilities	\$329,998	\$	-	\$	-	\$329,998

Notes to the Condensed Interim Financial Statements For the three and nine months ended July 31, 2024 and 2023 (Unaudited - Expressed in Canadian dollars)

#### 14. ECONOMIC DEPENDENCE

During the nine months ended July 31, 2024, One key customer (July 31, 2023 – three) contributed more than 10% to the Company's revenue for a total of \$7,344 or 73% (July 31, 2023 – \$242,829 or 86%).

	Nine months ended July 31, 2024			
Customer A	\$ -	\$	61,441	
Customer B	-		55,316	
Customer C	7,344		126,072	
	\$ 7,344	\$	242,829	

#### 15. SEGMENTED INFORMATION

The Company currently has one reportable operating segment, being the manufacturing and distribution of food products in Canada. As the operations comprise a single reporting segment, amounts disclosed also represent segment amounts. All long-term assets of the Company are located in Canada.

#### 16. PROPOSED TRANSACTION

On April 21, 2023, the Company had entered into a share exchange agreement with Glory Organic Juice Company Inc., Glory Juice Co. Vancouver Ltd. (collectively, "Glory Juice") and the shareholders of Glory Juice ("Vendors"). Pursuant to the agreement, the Company was to acquire all the issued and outstanding shares of Glory Juice and upon completion of the acquisition, each of the Glory Juice entities would become wholly-owned subsidiaries of the Company. On May 23, 2024, the Company announced its decision to forego the acquisition of Glory Juice.

### 17. SUBSQUENT EVENTS

On September 17, 2023, the Company completed a private placement, issuing 6,000,000 units at a price of \$0.05 per unit for gross proceeds of \$300,000. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the warrant holder to acquire one additional common share of the Company at an exercise price of \$0.06 for a period of 12 months commencing on the date of issuance.

On September 25, 2023, the Company issued 433,333 common shares upon the exercise of RSUs.

On September 26, 2024 Ajit Bhatti replaced Mohammad Fazil on the board of directors